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Background: Both gout and sleep apnoea are associated with the metabolic syndrome. Hyperuricaemia is also
prevalent in sleep apnoea syndrome. The objective of this study was to examine the association between gout and
sleep apnoea and other sleep disorders.
Methods: Data were taken from a validated database of general practice records from nine practices in the UK
between 2001 and 2008. People consulting for gout were identified via Read codes and each matched with four
controls for age, gender, practice and year of gout consultation. Sleep problems and confounding comorbidities
were also identified via Read codes. Medications were identified through a linked database of prescription records.
The association between gout and sleep disorders was assessed using a logistic regression model, adjusting for
ischaemic heart disease, hypertension, diabetes mellitus and diuretic use.
Results: 1689 individuals with gout were identified and each successfully matched to four controls. Amongst
those with gout, the prevalence of any sleep problem was 4.9%, sleep problems other than sleep apnoea 4.2%, and
sleep apnoea 0.7%, compared to 3.5%, 3.2% and 0.3% respectively in controls. Gout was associated with any sleep
problem (odds ratio (OR) 1.44; 95% confidence interval (CI) 1.11, 1.87), sleep problems other than sleep apnoea
(OR 1.36; 95% CI 1.03, 1.80), and sleep apnoea (OR 2.10; 95% CI 1.01, 4.39). On multivariable analysis, gout remained
significantly associated with any sleep problem (OR 1.39; 95% CI 1.06, 1.81) and sleep problems other than
sleep apnoea (OR 1.37; 95% CI 1.03, 1.82), however the association with sleep apnoea was attenuated (OR 1.48,
95% CI 0.70, 3.14).
Conclusions: Gout and sleep problems appear to be associated and clinicians should be aware of the co-existence
of these two conditions. Larger prospective epidemiological studies are required to explore causality.
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Gout is the most prevalent inflammatory arthropathy
and affects approximately 1.4% of adults [1,2]. It is as-
sociated with considerable co-morbidity. The metabolic
syndrome is present in over 60% of individuals with
gout, who are more than three times more likely to have
the metabolic syndrome than control subjects without
gout [3]. Individual components of the metabolic syn-
drome such as hypertension, obesity and diabetes melli-
tus are recognised to be independent risk factors for the
development of gout [4]. Insulin resistance is thought to
be the major mediator of hyperuricaemia, the primary* Correspondence: e.roddy@keele.ac.uk
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reproduction in any medium, provided the orrisk factor for the development of gout, in the metabolic
syndrome [5] although hypertension exerts renal vascu-
lar effects which also predispose to hyperuricaemia [6].
Perhaps, not surprisingly, given its association with trad-
itional cardiovascular risk factors, gout is associated with
a considerable burden of cardiovascular disease. How-
ever, recent prospective epidemiological studies have
suggested that gout confers additional independent car-
diovascular risk after adjustment for traditional risk fac-
tors [7-10].
Obstructive sleep apnoea syndrome is also a common
problem in primary care having a similar prevalence to
gout of approximately 1–4% [11,12], although there is
evidence that it is under-diagnosed in this setting [13,14].
Similar to gout, obstructive sleep apnoea syndrome isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tension, hyperlipidaemia, diabetes mellitus and cardio-
vascular disease [15-21]. It is less widely recognised that
serum uric acid levels are also frequently elevated in
patients with obstructive sleep apnoea syndrome. One-
quarter to one-half of patients with obstructive sleep ap-
noea syndrome have been shown to have hyperuricaemia
[19,22-24]. However, despite prevalent hyperuricaemia in
patients with obstructive sleep apnoea syndrome and
shared risk factors with gout of obesity and alcohol con-
sumption [25,26], little consideration appears to have been
given to the possibility of an association between obstruct-
ive sleep apnoea syndrome and gout [27]. A biologically
plausible mechanism exists to explain hyperuricaemia in
obstructive sleep apnoea syndrome. Hypoxia enhances nu-
cleotide turnover [28-30] generating purines which are
metabolised to uric acid.
We undertook a cross-sectional study within a re-
gional primary care consultation database with the aims
of, firstly, determining whether an association exists be-
tween gout and obstructive sleep apnoea syndrome and
other sleep disorders and, secondly, whether any such
association is independent of co-morbid traditional vas-
cular risk factors and vascular disease.
Methods
Study Setting
The data for this study are taken from two inter-linked
primary care databases: the Consultations in Primary
Care Archive (CiPCA) and the Prescriptions in Primary
Care Archive (PiPCA). These databases hold records of
all consultations and prescriptions of patients at 13 gen-
eral practices in North Staffordshire, UK, and have been
extensively described elsewhere [31]. The practices form
part of the Keele General Practice Research Partnership,
and regularly undergo cycles of training, assessment and
feedback regarding the quality of computerised morbid-
ity coding [32]. Comparable consultation rates have been
shown in CiPCA, as in national databases such as the
General Practice Research Database [31].
Practice staff are trained to enter at least one Read
code relating to each patient consultation. The Read code
classification is a hierarchy of morbidity, symptom and
process codes, organised by anatomical symptom, that be-
come more specific the lower down the coding hierarchy
one progresses [33].
All prescriptions issued at the participating practices
are automatically coded according to the British Na-
tional Formulary (BNF) and entered into the PiPCA
database. This ensures complete ascertainment of all
prescriptions issued.
All patients are allocated a unique identifier, allowing
their records to be linked over time and between the
CiPCA and PiPCA databases. For this study, data fromnine of the participating practices, who provided data to
the CiPCA and PiPCA databases for the complete period
from 2001 to 2008 and used version five of the Read
code system, were included.
Cases
Patients consulting their general practice and receiving a
Read code for gout between 2001 and 2008 were identi-
fied in the CiPCA database. A full list of the codes used
to identify cases is available from the authors on request.
We have previously examined the clinical records within
the CiPCA database of those people who received a
Read code for gout and found features of inflammation
and distribution of affected joints consistent with a diag-
nosis of gout [34]. The full consultation and prescription
record from 2001 to 2008 was downloaded for each of
these patients.
Controls
Controls were matched 4:1 to cases within the CiPCA
database. Controls were randomly selected using fre-
quency matching for age (within three-year bands), gen-
der and general practice. Controls had also consulted
their family physician for any non-gout condition within
the same calendar year as the first gout consultation
after 2001 was identified in cases. As with controls, all
consultations and prescriptions from 2001 to 2008 were
downloaded for these individuals.
Sleep disorders
Sleep disorders were identified in the medical records of
all cases and controls using Read codes. Specific Read
codes used in this search are available from the authors
on request. From these Read codes, each individual was
categorised as either having a sleep disorder recorded at
some time during the study period (2001 to 2008) or
not. Within those with a record of a sleep disorder, those
who specifically received a code for sleep apnoea were
identified and classified as having sleep apnoea. Those
with a Read code for a sleep disorder, but no code for
sleep apnoea were classified as having sleep problems
other than sleep apnoea; forming two mutually exclusive
groups.
Comorbid confounders
Type II diabetes mellitus, ischaemic heart disease (IHD),
hypertension, and use of diuretic drugs were considered
potential confounders in the association between gout
and sleep disorders. Read codes were used to identify
those cases and controls with type II diabetes mellitus,
IHD and hypertension within the 2001 to 2008 period
of interest. People with any prescriptions for diuretics
between 2001 and 2008 were identified from the PiPCA
database using British National Formulary (BNF) codes.
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ders are available from the authors on request.
Statistical analyses
The proportion of people with recorded sleep disorders
was described. Differences in the proportion of people
with these disorders in the cases and controls were com-
pared using confidence intervals, calculated in the pro-
gram Confidence Interval Analysis [35].
In order to assess the extent of clustering of patients
within general practices, a multi-level model with no in-
dependent variables was fitted. Based on the findings of
this model, multi- or single-level logistic regression mo-
dels were fitted as appropriate to assess the association
between gout and the presence of sleep disorders. Ad-
justment was made for the matching factors of age,
gender and year of consultation. Fractional polynomials
were used to assess the linearity of any association with
age and year of first consultation. Analyses were adjusted
for the potentially confounding comorbidities as de-
scribed above. Regression analyses were conducted in
Stata 11.2. The -mfp- command was used to estimate
fractional polynomials [36].
Ethical approval
The CiPCA database has ethical approval for case–con-
trol studies from the North Staffordshire local research
ethics committee (approval number 03/04). This approval
did not require individual informed consent, as data were
analysed anonymously.
Results
Case and control selection
Within the CiPCA database, 1689 people were iden-
tified as having consulted their GP for gout between
2001 and 2008. Cases were successfully matched to con-
trols (n = 6756) in a 1:4 ratio, as described above. Cases
were well-matched to controls in terms of the matching
variables (Table 1). The prevalence of hypertension, IHD
and type II diabetes mellitus was higher among gout
cases than controls, as was the prescription of diure-
tic medications.Table 1 Comparison of gout cases (n = 1689) and controls
(n = 6756) from the CiPCA dataset
Characteristic Case (n (%)) Control (n (%))
Age (mean (SD)) 62.5 (15.3) 62.5 (15.4)
Female gender 397 (23.5) 1588 (23.5)
Type II diabetes mellitus 212 (12.6) 615 (9.1)
Ischaemic heart disease 348 (20.6) 1065 (15.8)
Hypertension 919 (54.4) 2516 (37.2)
Diuretic prescription 903 (53.5) 2411 (35.7)Association between gout and sleep disorders
Overall, 3.7% (n = 316) of those studied had at least one
Read coded consultation for a sleep disorder, of which
10.1% (n = 32) had a Read code for sleep apnoea. The
proportion of people with any sleep disorder was higher
in the gout cases (4.9%) than in the controls (3.5%)
(1.4% difference, 95% CI: 0.3%, 2.5%) (Table 2). There
was no effect of clustering by general practice. Hence,
single level logistic regression models, adjusted for prac-
tice, were used for all analyses. After adjustment for
potentially confounding comorbidities and diuretic pre-
scriptions, participants continued to have 1.4 times the
odds of gout if they had a sleep disorder than if they did
not (OR 1.39; 95% CI 1.06, 1.81).
There was a 1.4-fold increased odds of gout in those
with a sleep disorder but no record of sleep apnoea
(OR 1.36; 95% CI 1.03, 1.80). After adjustment for po-
tential confounders, this association remained signifi-
cant (OR1.37; 95% CI 1.03, 1.82). Sleep apnoea was also
coded in a higher proportion of gout cases than controls
(0.7% of cases and 0.3% of controls). This amounted to a
two-fold increased odds of gout in those with sleep ap-
noea than in those without (OR 2.1; 95% CI 1.01, 4.39).
However, after adjustment for potentially confounding
comorbidities and medication prescriptions, this increase
in odds was attenuated 1.49 (95% CI 0.70, 3.14).
Discussion
To our knowledge, apart from one previous case report
[27], this is the first empirical epidemiological study to
explore an association between gout and obstructive
sleep apnoea syndrome. We examined the association
between gout and firstly all sleep problems combined
(“any sleep problem”) and secondly sleep problems re-
categorised as sleep apnoea and sleep problems other
than sleep apnoea. There were small but significant asso-
ciations between gout and both any sleep problem and
sleep problems other than sleep apnoea which remained
largely unchanged after adjusting for associated co-
morbid conditions. Although we found a two-fold in-
creased risk of sleep apnoea in those with gout on uni-
variable analysis, this was no longer statistically significant
after adjustment for multiple confounding variables.
The strengths of the study are its primary care setting
and the rigorous quality assurance processes undertaken
to ensure the robustness of computerized morbidity cod-
ing in the participating practices [32]. Limitations of our
study are worthy of acknowledgement. First, the cross-
sectional study design merely informs about association
and does not allow for any inferences concerning causal-
ity or direction of association. Second, use of primary
care consultation data relies upon a primary care diag-
nosis which may introduce misdiagnosis and hence
misclassification bias. In primary care, the diagnosis of
Table 2 Association of sleep problems and gout: results of logistic regression analyses
Cases Controls Unadjusteda OR (95% CI) Adjusted ORb (95% CI)
Any sleep problem 82 (4.9) 234 (3.5) 1.44 (1.11, 1.87) 1.39 (1.06, 1.81)
Sleep apnoea 11 (0.7) 21 (0.3) 2.10 (1.01, 4.39) 1.49 (0.70, 3.14)
Sleep problems other than sleep apnoea 71 (4.2) 213 (3.2) 1.36 (1.03, 1.80) 1.37 (1.03, 1.82)
OR, odds ratio.
For both models, age and year of first gout consultation are fitted linearly. aAdjustment made only for matching variables (age, year of first gout consultation,
gender, practice). bAdjustment made for matching variables and potentially confounding factors (type II diabetes mellitus, ischaemic heart disease, hypertension
and diuretic prescription).
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whereas definitive diagnosis requires crystal identifica-
tion [39]. It has previously been suggested that gout is
frequently over-diagnosed in primary care [40]. However,
primary care consultation records have been widely used
in gout research [1,2,41,42] and, although not under-
taken during the current analysis, in a previous study
undertaken using consultation data from the CiPCA
database, scrutiny of consultation free text recorded by
general practitioners confirmed features of inflammation
and distribution of affected joints generally consistent
with a diagnosis of gout [34]. Diagnosis in primary
care is also an important consideration for obstructive
sleep apnoea syndrome which is frequently unrecognized
[14,43]. Indeed, the prevalence of obstructive sleep ap-
noea syndrome is lower in our study than in previous
general population studies which have employed more
definitive diagnostic methods [11,12]. It seems likely
therefore that some patients with obstructive sleep ap-
noea syndrome will have gone unrecognised altogether
[13,14,43] although it is also possible that some may
have been misdiagnosed as having another sleep prob-
lem, in which case they would have been classified firstly
as “any sleep problem” and then as a “sleep problems
other than sleep apnoea” in this study. However, previ-
ous studies indicate that a diagnosis of obstructive sleep
apnoea made by a general practitioner is usually correct
[14,44]. A further limitation is that obesity and alcohol
which are risk factors for both gout and obstructive
sleep apnoea syndrome [25,26] are infrequently coded in
primary care databases and hence we were unable to ad-
just for either of these important potential confounding
variables. We acknowledge also that our analysis is likely
to have been under-powered to detect a significant as-
sociation between gout and obstructive sleep apnoea
syndrome. However, we believe that this is a novel and
interesting potential association which has not been
previously studied and for which there is a biologically
credible underlying mechanism, namely enhanced deg-
radation of adenosine triphosphate in the presence of
hypoxia leading to increased substrate provision for the
purine metabolic pathway of which uric acid is the end-
product in humans [28-30] and prevalent hyperuricae-
mia in obstructive sleep apnoea syndrome [19,22-24].These preliminary findings provide justification for a lar-
ger prospective epidemiological study to examine in
more detail the possibility that obstructive sleep apnoea
syndrome is a risk factor for gout.
We found a significant association between gout and
sleep problems other than sleep apnoea. These disorders
consisted of a heterogeneous group of conditions, most
commonly insomnia and non-specific sleep disorders
(data not shown). To our knowledge, associations bet-
ween these conditions and either gout or hyperuricaemia
have not been studied previously and we are not aware
of biological mechanisms to link them with either hy-
peruricaemia or crystal formation. More detailed study
of this association, which specific sleep disorders are as-
sociated with gout, and the mechanisms underlying this
association is warranted.
Notwithstanding the lack of association between gout
and obstructive sleep apnoea syndrome after adjustment
for confounding factors, our univariate analysis suggests
that gout and obstructive sleep apnoea syndrome can
co-exist and hence clinicians should be aware of gout as
a potential cause of painful joints in patients with ob-
structive sleep apnoea syndrome and also of the latter as
a significant cause of excessive sleepiness in patients
with gout. Prompt and accurate recognition of obstruct-
ive sleep apnoea syndrome is particularly important be-
cause of the associated risk of motor vehicle accidents
[45] and legal requirements not to drive unless treated
[46]. Furthermore, treatment of obstructive sleep apnoea
syndrome with continuous positive airways pressure
(CPAP) has been shown to improve certain parameters
of the metabolic syndrome such as hypertension [47]
and hyperlipidaemia. It is plausible that lowering of uric
acid levels with CPAP treatment would theoretically lead
to better control of gout although to our knowledge the
effect of CPAP on uric acid levels has not been studied
and further research is required. Further large prospect-
ive epidemiological studies are required to explore this
association and establish causality in more detail.
Conclusions
Our findings support an association between gout and
sleep disorders, although the association with obstruc-
tive sleep apnoea syndrome does not appear to be
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ever, the potential co-existence of these two common
conditions is an important message for clinicians and
deserves wider recognition. Future studies should focus
on establishing the independence of this association and
causality and examine whether treatment strategies bene-
fit both conditions.
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